Association of radiotherapy for prostate cancer and second primary colorectal cancer : a US population-based analysis

© 2023. Springer Nature Switzerland AG..

BACKGROUND: Radiotherapy (RT) is a common treatment for prostate cancer, yet the risk of second primary colorectal cancer (SPCRC) in patients with prostate cancer undergoing RT has not been adequately studied.

METHODS: This study employed a population-based cohort design using the US Surveillance, Epidemiology, and End Results (SEER) database to identify individuals diagnosed between January 1975 and December 2015. The cumulative incidence of SPCRC was estimated using Fine-Gray competing risk regression. Poisson regression analysis was used to estimate the risk associated with RT. Survival outcomes of patients with SPCRC were evaluated using the Kaplan-Meier method.

RESULTS: A total of 287,607 patients diagnosed with prostate cancer were identified. The cumulative incidences were higher in patients who did not receive RT (2.00%) compared to those who underwent RT (2.47%) after 25 years. After adjustment for multiple variables, RT was associated with an increased risk of developing combined SPCRC (adjusted HR 1.590). Additionally, the overall survival was significantly lower in patients who developed colorectal cancer after receiving RT as compared to those who did not receive RT.

CONCLUSION: These findings underscore the need for diligent long-term monitoring and effective management strategies to detect SPCRC in patients treated with RT for prostate cancer.

Medienart:

E-Artikel

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Zur Gesamtaufnahme - volume:28

Enthalten in:

Techniques in coloproctology - 28(2023), 1 vom: 14. Dez., Seite 14

Sprache:

Englisch

Beteiligte Personen:

Tang, W [VerfasserIn]
Zhou, L-J [VerfasserIn]
Zhang, W-Q [VerfasserIn]
Jia, Y-J [VerfasserIn]
Ge, M-W [VerfasserIn]
Hu, F-H [VerfasserIn]
Chen, H-L [VerfasserIn]

Links:

Volltext

Themen:

Colorectal cancer
Journal Article
Prostate cancer
Radiotherapy
SEER
Second primary cancer
Survival analysis

Anmerkungen:

Date Completed 16.12.2023

Date Revised 06.02.2024

published: Electronic

Citation Status MEDLINE

doi:

10.1007/s10151-023-02883-2

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM365864811